Johnson & Johnson (NYSE:JNJ) says it is abandoning plans to buy Takeda Pharmaceutical's (NYSE:TAK) TachoSil surgical patch product due to regulatory issues.
Takeda had announced the sale of TachoSil to J&J subsidiary Ethicon for $400M last May.
Federal Trade Commission Chairman Joseph Simons earlier cited potential regulatory issues over the deal because J&J also sells Evarrest, the only other U.S.-approved fibrin sealant patch designed to stop bleeding during surgery.
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn
Mark H. Anania, a partner at McCarter & English, LLP, has been named President of the New Jersey Intellectual Property Law Association
Cohen Seglias Pallas Greenhall & Furman PC is pleased to announce that Anthony H. Chwastyk has joined the
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2025 citybuzz
